[Composition]

This product is a compound preparation, with each 2ml vial containing potassium dihydrogen phosphate 0.435g and dipotassium hydrogen phosphate (triclinic water) 0.639g.

[Characteristics]

This product is a colorless and clear liquid.

[Indications]

Mainly used as a phosphorus supplement in total parenteral nutrition therapy, for patients who have undergone moderate or above surgery or other trauma and need to fast for more than 5 days. It can also be used for hypophosphatemia caused by certain diseases.

[Specifications]

2ml: 0.639g K2HPO4·3H2O and 0.435g KH2PO4

[Dosage and Administration]

For patients who cannot eat for a long time, the dosage should be determined by the doctor based on the condition and test results. The product should be diluted at least 200 times and administered intravenously by infusion. In general, in total parenteral nutrition therapy, 2.5ml of this product (equivalent to [PO4] 8 millimoles) should be added per 1000 kilocalories of energy, and the infusion rate should be controlled.

[Adverse Reactions]

Excessive use of this product may lead to hyperphosphatemia, hypocalcemia, muscle tremors, spasms, gastrointestinal discomfort, etc. If moderate symptoms occur, the medication should be stopped immediately.

[Precautions]

This product is strictly prohibited for direct injection. It must be diluted at least 200 times and administered intravenously by infusion under the guidance of a doctor, and the infusion rate must be controlled. This product is only intended for patients who cannot eat. It is not suitable for patients with renal failure. When compatibility with calcium-containing injections, precipitation may occur and should not be used.

[Use in Pregnant and Lactating Women]

Not yet clear.

[Use in Children]

Currently, there is no experience of using this product in children.

[Use in the Elderly]

Generally, patients with high collar have lower physiological functions. When using this product, start with a low dose and carefully observe the patient's symptoms.

[Drug Interactions]

Not yet clear.

[Overdose]

Not yet clear.

[Pharmacology and Toxicology]

It participates in the glycolysis of carbohydrate metabolism, constitutes phospholipids in the cell membrane, and is an important component of RNA, DNA, and many coenzymes. Phosphorus also participates in the storage, conversion, transport of energy, and regulation of body fluid buffering function.

[Pharmacokinetics]

In healthy adults, the daily intake of phosphorus is about 900mg, which is approximately equivalent to the daily standard dose. About 60% of the required phosphorus is rapidly absorbed in the duodenum, and the remaining is absorbed in other parts of the intestine. Vitamin D and parathyroid hormone can promote the intestinal absorption of phosphorus, while calcitonin can inhibit the intestinal absorption of phosphorus. When there is an excessive amount of metal ions such as Ca2+, Mg2+, Fe2+, Al3+ in the food, they can combine with phosphate to form insoluble salts, hindering the absorption of phosphorus. The kidney is the main organ for regulating phosphorus balance, and about 90% of the phosphorus excreted daily is excreted in urine, while the rest is excreted in the gastrointestinal tract and skin. The total phosphorus content in the human body is about 400-500g, of which about 85% is present in bone marrow, 6% in muscle tissue, and 9% in other tissues. Inorganic phosphate in the blood contains about 12% bound to plasma proteins, 33% is in the bound form, and 44% is in the alkaline and acid forms. The latter two are part of the complex form and can be ultrafiltered.

[Storage]

Store in a light-resistant, sealed condition (10-30°C).

[Packaging]

Ampoules, 8 vials per box.

[Shelf Life]

24 months

[Standard]

WS1-(X-050)-2005Z-2013

[Approval Number]

National Medical Products Administration Approval Number H20094204